Supernus Pharmaceuticals (SUPN)

Supernus Pharmaceuticals (SUPN) Financial Statements


Supernus Pharmaceuticals Financial Overview

Supernus Pharmaceuticals's market cap is currently ―. The company's EPS TTM is $0.388; its P/E ratio is 69.30; Supernus Pharmaceuticals is scheduled to report earnings on February 27, 2024, and the estimated EPS forecast is $0.41. See an overview of income statement, balance sheet, and cash flow financials.
Sep 23Jun 23Mar 23Dec 22Sep 22
Income Statement-
Total Revenue$ 153.88M$ 135.56M$ 153.76M$ 167.33M$ 177.35M
Gross Profit$ 134.28M$ 114.47M$ 130.30M$ 144.37M$ 151.47M
EBIT$ 9.89M$ -16.22M$ 10.52M$ 25.01M$ 1.28M
EBITDA$ 31.78M$ 4.51M$ 31.62M$ 45.71M$ 23.05M
Net Income Common Stockholders$ -15.98M$ -831.00K$ 16.95M$ 25.48M$ 1.75M
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments$ 200.19M$ 151.66M$ 58.44M$ 461.33M$ 391.79M
Total Assets$ 1.29B$ 1.29B$ 1.79B$ 1.70B$ 1.69B
Total Debt$ 33.84M$ 34.18M$ 741.66M$ 437.97M$ 444.22M
Net Debt$ -166.35M$ -117.48M$ 683.22M$ -23.37M$ 52.43M
Total Liabilities$ 372.97M$ 373.19M$ 879.66M$ 816.30M$ 840.33M
Stockholders Equity$ 912.19M$ 919.91M$ 912.15M$ 886.20M$ 852.80M
Cash Flow-
Free Cash Flow$ 35.73M$ -19.82M$ 50.46M$ 27.56M$ 13.69M
Operating Cash Flow$ 35.88M$ -19.66M$ 50.74M$ 27.56M$ 13.84M
Investing Cash Flow$ 34.63M$ 61.09M$ 238.13M$ -48.77M$ -82.23M
Financing Cash Flow$ -230.00K$ -478.92M$ 80.17M$ 2.83M$ 6.46M
Currency in USD

Supernus Pharmaceuticals Earnings and Revenue History

Supernus Pharmaceuticals Debt to Assets

Supernus Pharmaceuticals Cash Flow

Supernus Pharmaceuticals Forecast EPS vs Actual EPS

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis